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6 ABSTRACT: Dextran-coated iron oxide magnetic particles modified with ligand 22/8, a protein A mimetic ligand, were
7 prepared and assessed for IgG purification. Dextran was chosen as the agent to modify the surface of magnetic particles by
8 presenting a negligible level of nonspecific adsorption. For the functionalization of the particles with the affinity ligand toward
9 antibodies, three methods have been explored. The optimum coupling method yielded a theoretical maximum capacity for
10 human IgG calculated as 568 ± 33 mg/g and a binding affinity constant of 7.7 × 104 M−1. Regeneration, recycle and reuse of
11 particles was also highly successful for five cycles with minor loss of capacity. Moreover, this support presented specificity and
12 effectiveness for IgG adsorption and elution at pH 11 directly from crude extracts with a final purity of 95% in the eluted fraction.
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1. INTRODUCTION
14 Full antibodies and engineered antibody formats can be
15 designed to bind to a diversity of antigens with high specificity,
16 and further conjugated with other therapeutics for increased
17 efficiency.1 For the in vivo administration of antibodies,
18 demanding production and purification processes are required
19 in order to avoid contaminations and produce safe, pure, and
20 consistent products. Simultaneously, industries have the
21 challenge to reduce total manufacturing costs. Downstream
22 processing can account for 50−80% of the total production
23 costs; therefore, there is the need to design purification
24 strategies that will target high purity and product yield as well
25 as cost minimization.2,3
26 Affinity-based methodologies are widely employed on
27 traditional antibody purification processes, and are based on
28 the selective recognition between the antibody molecule and a
29 complementary ligand immobilized in a solid matrix, commonly
30 agarose or derivatives.3 Nonspecific interactions are reduced
31 with increased yield and contaminants can be eliminated in a
32 single step. The affinity ligands mostly used to capture
33antibodies are biospecific ligands which are natural immuno-
34globulin binding ligands (protein A, protein L).4,56 However,
35these ligands are costly, labile, and can leach under certain
36conditions. An alternative and promising choice is the use of
37synthetic affinity ligands mimicking the biological receptors.7−9
38Although presenting lower binding constants, the purity
39obtained with the biomimetic ligands is still high with the
40advantages of being inexpensive, scalable to produce, durable
41and extraordinarily stable under harsh conditions.3 A good
42example of biomimetic ligands toward antibodies is ligand 22/8,
43a protein A mimetic.10 In addition, the support for ligand
44attachment is also a key step for binding the target molecule.
45The immobilization of ligands on agarose beads has been
46extensively studied on literature.3,7 However, packed bed
47chromatography and bed expanded systems present some
48limitations, namely clogging and diffusion limitations.3,11
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49 Iron oxide magnetic particles (MPs) appear as a challenging
50 and a suitable choice for bioseparation applications because this
51 support can contribute to cost reduction and process
52 integration.2,3 MPs present attractive features such as super-
53 paramagnetism, which greatly facilitates manipulation, recovery,
54 and reutilization, particularly in high-gradient magnetic
55 separation devices.12,13 Other advantageous characteristics of
56 MPs concern the small size of the particles providing a high
57 surface area to volume and minimum diffusion limitations.14,15
58 MPs present low colloidal stability because of the highly active
59 surface and high surface area to volume ratio, which increases
60 the particles agglomeration. Both phenomena have impact on
61 the size, shape, and stability of the particles. In solution, the
62 impact of these might bring some disadvantages in the
63 applicability of these supports.15,16 The coating of MPs appears
64 as an essential strategy for particle stabilization, and different
65 coating agents can be applied. MPs coating with polymers,
66 particularly biopolymers such as polysaccharides, attracted
67 attention of researchers as these are known to increase
68 biocompatibility, chemical functionality, and colloidal stability
69 of different materials. In addition, biopolymers are renewable,
70 nontoxic and biodegradable which make them an environ-
71 mental and sustainable choice.15 Some of the polysaccharides
72 most used for covering MPs, include agarose,17 chitosan,18
73starch,19 dextran,20 and gum Arabic.21,22 Dextran, a neutral
74polysaccharide produced by lactic acid bacteria, is a conven-
75tional polymer used for coating MPs. MPs coated with dextran
76(MPs_Dex) are mostly used in biomedical applications for
77resonance magnetic imaging and there are already preparations
78available in the market.15 These supports were also explored for
79bioseparation and biosensing applications.23,24 In the biosepa-
80ration field, dextran-coated MPs have already been applied for
81the separation of proteins,25,26 cells,27 organelles,28 and for
82isolation of target bacteria by immunomagnetic particles,29
83through the exploitation of the natural interactions between
84sugars and biological receptors.
85This work focused on the preparation of a new magnetic
86support, based on iron oxide magnetic particles coated with
87dextran for bioseparation processes, taking into account the
88characteristics of iron oxide magnetic particles coated with gum
89Arabic (MPs_GA) previously studied.21 The novelty of this
90work relies on the combination of a low cost and inert polymer
91with a robust synthetic ligand mimicking protein A for the
92purification of IgG from purified and unpurified mixtures.
2. EXPERIMENTAL PROCEDURE
93Materials. (3-Aminopropyl)triethoxysilane (APTES) 98%, 3-
94hydroxyanilin 98%, 4-amino-1-naphtol hydrochloride 90%, cyanuric
Figure 1. Schematic representation of the synthetic affinity ligand 22/8 Immobilized onto MPs coated with dextran by three different methods:
method A, the ligand 22/8 was used in solution phase with a six carbon spacer; method B, the ligand 22/8 was also used in solution phase but
without spacer; and method C, the ligand 22/8 was directly synthesized onto the support (ChemDraw 11).
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95 chloride 99% were acquired from Aldrich (Sintra, Portugal). Sodium
96 hydroxide 99% was purchased from Panreac (Cascais, Portugal).
97 Albumin from bovine serum, dextran from Leuconostoc mesenteroides,
98 glutaric dialdehyde 50 wt % sol in water, gum arabic from acacia tree,
99 iron(III) chloride hexahydrate 98%, iron(II) chloride tetrahydrate
100 99%, and N,N-dimethylformamide 99% were acquired from Sigma
101 (Sintra, Portugal). Anthrone 97%, sodium bicarbonate 98%, and
102 sulfuric acid 98% were from Sigma−Aldrich (Sintra, Portugal). Human
103 normal immunoglobulin (Gammanorm) was purchased from
104 Octapharma (Lisboa, Portugal). Protein quantification assay used
105 was bichinchoninic acid (BCA) kit from Sigma. For SDS-PAGE gels,
106 the reagents used were 30% acrylamide/bis solution 37.5:1, sodium
107 dodecyl sulfate solution 10% purchased from BIO-RAD. Ammonium
108 persulphate 98% (PSA), N,N,N,N-tetramethylethylenediamine 99%
109 (TEMED), and bromphenol blue sodium salt were acquired from
110 Roth (BetaLab, Queluz, Portugal). Glycerol 99% purchased from
111 Sigma−Aldrich (Sintra, Portugal). SDS micropellets 99% (sodium
112 dodecyl sulfate), tris base 99.9% ultrapure for molecular biology, and
113 glycine 99% ultrapure for molecular biology were purchased from
114 NZYTech (Lisboa, Portugal). 2-Mercaptoethanol 99% purchased from
115 Aldrich (Sintra, Portugal). Hydrochloric acid 37% (concentrated) was
116 acquired from Panreac (Cascais, Portugal). To stain polyacrylamide
117 gels , we used the Silver Stain Plus kit from BIO-RAD (Amadora,
118 Portugal). LMW-SDS Marker Kit (18.5 kDa −96 KDa) was from
119 NZYTech (Lisboa, Portugal).
120 Methods. Synthesis, Amination, Stability Study, and Character-
121 ization of Bare and Dextran-Coated MPs. Bare MPs and dextran-
122 coated MPs were synthesized by the coprecipitation of FeCl3 and FeC2
123 salts, using a Fe2+/Fe3+ molar ratio of 0.5, through the addition of a
124 base under an inert atmosphere, following the Massart method.30 The
125 syntheses were performed at room temperature for the bare MPs and
126 at 60 °C for the dextran-coated MPs (MPs_Dex). For the MPs_Dex,
127 2.0 g of a 50 mg/mL aqueous solution of the biopolymer was added
128 dropwise immediately after the addition of the iron solution. The
129 synthesized MPs were washed several times with distilled water using a
130 magnet for separation. To quantify the yield of biopolymer coating
131 MPs, we analyzed the amount of biopolymer in the washes after
132 synthesisby the anthrone method.31 MPs were then aminated by using
133 3-aminopropyltriethoxy silane (APTES),21 yielding amination den-
134 sities of 214 ± 44 μmoL NH2/g MPs. Finally, to evaluate the storage
135 stability at 4 °C and the stability of the supports on amination, we
136 analyzed all the washes performed in the intermediate steps by the
137 anthrone method to determine the quantity of biopolymer released.
138 All samples were characterized by Fourier transform infrared (FTIR)
139 spectroscopy on a Perkin-Elmer Spectrum BX instrument. Samples
140 were prepared by grounding and mixing with KBr in a proportion of
141 1:100. The magnetization of the magnetic particles in solution were
142 characterized by using a vibrating sample magnetometer (VSM)
143 (DSM 880 VSM) at INESC-MN facilities (Lisbon, Portugal). The
144 samples were prepared in milli-Q water with a concentration of 6.1
145 mg/mL and were used 30 μL of each sample in a vertical quartz rod.
146 Transmission electron microscopy (TEM) was utilized for the
147 characterization of particle morphology and estimation of the size of
148 the magnetic core. The dried particle samples were prepared by
149 evaporating dilute suspensions on a carbon-coated film and TEM
150 performed in an Analytical TEM Hitachi 8100 with Rontec standard
151 EDS detector and digital image acquisition. For all supports the
152 physical properties (hydrodynamic diameters and zeta potential) were
153 determined by Dynamic light scattering (DLS), using a Zetasizer Nano
154 ZS from Malvern. For these analyses, samples with a final
155 concentration of 0.05 mg/mL in milli-Q water were prepared.
156 Immobilization of the Biomimetic Ligand 22/8 onto Dextran-
157 Coated MPs. For the immobilization of the biomimetic ligand 22/8
f1 158 onto MPs_Dex, three different methods were tested (Figure 1). In
159 method A, the ligand 22/8 has a six carbon space arm and was
160 previously synthesized in solution phase and purified7 by Dr. Abid
161 Hussain from our group. For the immobilization procedure, the
162 aminated particles (10 mg/mL) were washed five times with distilled
163 water and resuspended in a solution of glutaraldehyde with a final
164 concentration of 5% (v/v). The suspensions were sonicated for 10 min
165and subsequently incubated for 1 h at room temperature with constant
166shaking. Afterward, the particles were washed five times with milli-Q
167water. The support was then incubated in a 1:1 stoichiometry (taking
168into account the number of amines available) with the ligand 22/8
169previously dissolved in DMF:H2O (50:50) and centrifuged for 5 min
170at 13000 rpm to make sure the insoluble part was discarded. The
171incubation proceeded for 1 h at room temperature at 300 rpm in an
172orbital shaker. Finally, to block the remaining functional groups, we
173washed modified supports five times with distilled water and were
174incubated 1 h at room temperature with constant shaking in the
175presence of a solution of 100 mMol/L glycine in distilled water.
176For method B, the ligand 22/8 was synthesized in solution phase32
177and kindly provided by Telma Barroso from our group. For this
178immobilization procedure the aminated MPs were incubated with 5
179mol equiv (taking into account the number of amines available) of the
180ligand 22/8 dissolved in DMF:H2O (1:12) and with 1 equivalent of
181sodium bicarbonate. Incubation occurred for 2 days at 85 °C with
182constant shaking. In methods A and B, final washes were collected in
183order to quantify the amount of ligand bound to the particles (by
184measurement of absorbance at 280 nm). However, it was not possible
185to quantify the exact amount of ligand bound because of the extremely
186low solubility of the ligand.
187Finally, in method C, ligand 22/8 was synthesized directly on the
188particles. The aminated support was resuspended in 50% (v/v)
189acetone/water and reacted with 5 mol equiv (according to the amount
190of amines available) of Cyanuric chloride, dissolved in acetone, during
1912 h at 0 °C at 300 rpm. In the end of this reaction, the MPs were
192washed one time with acetone, one time with 50% (v/v) acetone/
193water and finally five times with water. The first nucleophilic
194substitution on triazine ring was then performed by adding 2
195equivalents (relative to the amount of amines) of 3-hydroxyanilin in
196water. This reaction proceeded for 24 h with stirring at 30 °C and after
197the reaction the particles were washed five times with water. Finally,
198for the second nucleophilic substitution, 5 mol equiv of 4-amino-1-
199naphtol- hydrochloride, in the presence of 5 equiv. of sodium
200hydroxide, dissolved in 50% (v/v) DMF/water, were added to the
201reaction and left to incubate for 48 h with stirring at 90 °C.
202After every procedure in methods A, B, and C, the particles were
203washed sequentially with 50% (v/v) DMF/water, water, and finally
204resuspended in water for storage.21
205Assessment of Human IgG and Bovine Serum Albumin Binding
206to Affinity Magnetic Supports. The MPs_Dex modified with affinity
207ligand 22/8 (250 μL at 6.0 mg/mL) were tested with a pure solution
208of human IgG (hIgG), and with a pure solution of Bovine Serum
209Albumin (BSA). The particles suspensions were washed with
210regeneration buffer (0.1 M NaOH in 30% (v/v) isopropanol),
211followed by deionized water to neutralize the pH. These cycles of
212washes were repeated two times. Then, particles were equilibrated with
213binding buffer (50 mM phosphate, pH 8). After preparation of the
214supports, 250 μL of a hIgG or BSA solution in binding buffer (1 mg/
215mL) was added to the particles and incubated for 15 min at room
216temperature with constant stirring, after which the supernatants were
217separated by magnetic separation and removed. Particles were then
218washed five times using binding buffer (250 μL) following the same
219methodology. Bound protein was then eluted with a 50 mM Glycine−
220NaOH, pH 11 buffer. Reuse of the modified supports were repeated
221five times for the binding of hIgG, where after each cycle of adsorption
222and elution the supports were regenerated two times using
223regeneration buffer followed by deionized water to neutralize the
224pH. All samples were analyzed by BCA assay (microplate reader
225assay), in order to quantify the amount of protein bound to and eluted
226from the supports.21 Nonmodified particles (MPs and MPs_Dex)
227were tested at the same time and in the same conditions. To assess
228biopolymer and iron leaching, we incubated the magnetic supports
229separately with binding, elution, and regeneration buffers, and the
230supernatants recovered by magnetic separation. The amount of
231biopolymer and iron in the supernatants were quantified by the
232anthrone31 and magnetite33 methods, respectively. Adsorption
233isotherms of hIgG on the magnetic supports were estimated by
234partition equilibrium experiments. Solutions of hIgG (0−18 mg/mL;
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235 250 μL) in phosphate buffer (50 mM, pH 8) were incubated with 250
236 μL at 6.1 mg/mL of MPs_Dex functionalized with ligand 22/8 by
237 method C, as previously described in literature.21
238 Assessment of Monoclonal Antibody Magnetic Purification from
239 Crude Extracts. The functionalized (MPs_Dex_22/8 by Method C)
240 and nonfunctionalized supports (MPs_Dex) (500 μL with 54 mg/mL)
241 were washed sequentially with regeneration and binding buffers, as
242 described above, and then incubated for 15 min at 4 °C with 500 μL of
243 a CHO cell culture supernatant. The solution in which the particles
244 were suspended was removed by magnetic separation, and then MPs
245 were washed five times with binding buffer (500 μL). After washing,
246 MPs were divided in two equal portions and protein recovery was
247 tested for two elution buffers: (i) 50 mM glycine−HCl, pH 3 and (ii)
248 50 mM glycine−NaOH, pH 11. All collected samples (loading,
249 flowthrough, and elutions) were analyzed by SDS-PAGE 12.5%
250 Acrylamide/Bisacrylamide in denaturing conditions and stained with
251 Silver Staining kit (BioRad). A BCA assay was also performed in order
252 to quantify the amount of total protein in each of the samples
253 collected.
3. RESULTS AND DISCUSSION
254 Preparation and Characterization of Affinity Magnetic
255 Supports. Magnetic supports were prepared by the chemical
256coprecipitation of iron salts and coated with dextran, a neutral
257polysaccharide well-known as a coating agent. Upon MPs
258coating, dextran presented high stability toward storage and
259modification with amino-silanes, as no biopolymer was released
260over a period of 160 days and during the amination step. The
261prepared magnetic particles were then characterized by FTIR,
262 f2VSM, TEM and DLS. The analysis of FTIR spectra (Figure 2 −
263A) confirmed the presence of dextran on the surface of the
264particles. The characteristic dextran peaks at 1427 cm−1, due to
265C−H bond bending, and around 1000 cm−1, due to the
266stretching vibration of the alcoholic hydroxyl (C−OH), were
267visible in the spectra of coated MPs. The characterization by
268TEM revealed the existence of spherical magnetic cores (Figure
2692C) with an average diameter of 12 nm (Figure 2D) and a size
270distribution between 8−12 nm, as observed previously by
271Batalha and co-workers.21 The spherical magnetic cores tend to
272form agglomerates, more pronounced upon dextran coating, as
273assessed by an increase on the hydrodynamic diameter (Figure
2742E) of MPs_Dex. This phenomenon has already been observed
275in other works and might be attributed to the noncovalent
276interactions between the coating biopolymers and neighbor
Figure 2. (A) Magnetic particle characterization by FTIR spectra for dextran (curve a), bare MPs (curve b), dextran-coated MPs (curve c), and
MPs_Dex functionalized with 22/8 (curve d). (B) VSM curves for bare MPs (curve a), dextran-coated MPs (curve b), and MPs_Dex functionalized
with 22/8 (curve c). (C) TEM image of dextran-coated MPs. (D) Grain size distribution from TEM. (E) Hydrodynamic diameter. (F) Zeta
potential (n = 2).
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277 particles.21,34 The hydrodynamic diameter for MPs_Dex
278 agglomerates decreases slightly upon modification with ligand
279 22/8, since this functionalization can create steric restrictions,
280 alteration of surface charge and increased hydrophobicity.21
281 Through zeta potential analysis (Figure 2F), the presence of the
282 dextran was confirmed as well as the modification of the surface
283 of the particles with ligand 22/8. When coated with dextran, the
284 particles presented a zeta potential of −1.88 mV, because of the
285 neutral charge of the biopolymer, which is corroborated with
286 the values determine by Xu and co-workers.35 After chemical
287 modification of MPs_Dex with ligand 22/8, the zeta potential
288 of the supports became more negative. These changes in the
289 zeta potential show a surface charge rearrangement due to the
290 presence of new functionalization groups.21
291 Finally, through VSM analysis, it was possible to ascertain the
292 magnetic properties of the supports. The curves represented in
293 Figure 2B show reversibility and symmetry which represents a
294 typical no hysteresis curve characteristic of the super-
295 paramagnetic behavior of the particles synthesized. In terms
296 of saturation magnetization, the values obtained were 41.5
297 emu/g for bare MPs (0.9955), 52.0 emu/g for MPs_Dex
298 (0.9946), and 62.0 emu/g for MPs_Dex modified with ligand
299 22/8 (0.9933). The saturation magnetization value obtained for
300 the bare MPs is consistent with the values referenced in the
301 literature.36
302 Affinity Magnetic Separation of Antibodies. Our group
303 has previously shown the suitability of gum Arabic as a coating
304 agent to produce magnetic supports modified with the affinity
305 ligand 22/8 for antibody separation. However, the charged
306 nature of gum Arabic can interfere with the adsorption of
307biocomponents and increase nonspecific interactions. The
308inertness of MPs_Dex magnetic supports for binding hIgG
309has been assessed and compared with bare agarose, the
310traditional support for chromatography, bare MPs and gum
311Arabic coated MPs. Agarose presented the lowest nonspecific
312interactions (0 mg/g hIgG bound to unmodified agarose),
313followed by MPs_Dex (4 ± 4 mg of hIgG per gram of dried
314MPs), MPs coated with gum arabic (28 ± 3 mg of hIgG per
315gram of dried MP), and bare MPs (60 ± 2 mg if hIgG per gram
316of dried MP).21 MPs_Dex presented seven times less capacity
317for binding to hIgG, when compared with gum Arabic coated
318MPs.21 The differences in the chemical composition of the
319biopolymers can explain the different reactivity they impair to
320the magnetic supports. Nonetheless, coating MPs with
321biopolymers is likely to create a net of porous structures that
322leaves reactive iron oxide partly exposed to create interactions
323and might have some contribution in the nonspecific
324adsorption of each support.MPs_Dex particles were further
325on explored for hIgG purification from pure solutions, through
326the conjugation of a synthetic affinity ligand mimicking protein
327A, named as ligand 22/8. Three different methods for the
328covalent attachment of the synthetic ligand onto MPs have
329been tested (Figure 1). In method A, ligand 22/8 was
330synthesized in solution-phase with a six carbon spacer. In
331method B, ligand 22/8 was also synthesized in solution-phase
332but without a six carbon spacer. Finally, for method C, ligand
33322/8 was synthesized directly on the solid support. In method
334A, there is the need to use a strong cross-linker
335(glutaraldehydem) which can also react with amine groups
336from neighboring particles, therefore reducing the free aldehyde
Figure 3. (A) Binding and elution of hIgG to MPs_Dex modified with ligand 22/8 (n = 2); (B) binding of BSA and hIgG to MPs_Dex modified
with ligand 22/8 through Method C (n = 2); (C) reutilization of MPs_Dex modified with ligand 22/8 through Method C for binding and elution of
hIgG (n = 2); and (D) binding of hIgG at the surface of MPs_Dex modified with ligand 22/8 by Method C. Representation of q (the amount of
bound hIgG in equilibrium per mass of solid support) as function of Ceq (the concentration of hIgG in equilibrium). Experimental data were fitted
with the expression q = (Qmax × Ceq)/(Kd + Ceq) for the Langmuir isotherm (OriginLab 6.1 software), where Qmax corresponds to the maxium
concentration of the matrix sites available to the partitioning solute (which can also be defined as the binding capacity of the adsorbent), and Kd is
the dissociation constant (n = 2).
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337 groups available to react with the amine groups from the ligand.
338 In addition, the solubility of the ligand is very poor. Method B
339 is performed at high temperature (80−90 °C), at which the less
340 reactive chloride of the ligand is substituted. Consequently, the
341 quantity of ligand that is immobilized on the support may be
342 compromised. In the case of method C, this is a multistep
343 reaction where the coupling of the triazine ring is done at 0 °C
344 through the most reactive chloride, and therefore less likely to
345 result in low reaction yields. Previous works have also shown
346 that immobilization of very insoluble triazine ligands through
347 direct directly on the solid support yields best results for
348 protein adsorption.9
349 By analyzing the quantity of hIgG bound and eluted from the
f3 350 supports (Figure 3A), method A revealed to be the less suitable
351 method followed by method B. Method C seems to be the best
352 method to immobilize ligand 22/8 and to produce affinity
353 magnetic supports toward IgG To assess the recovery of
354 protein, we studied the elution buffer 50 mM glycine−NaOH,
355 pH 11, because of iron leaching at acidic pH, previously
356 observed.21 In Method A it was not possible to quantify eluted
357 protein. In method B, it was possible to elute 42 ± 1 mg of
358 hIgG eluted/g of MPs which corresponds to 37% of the bound
359 protein, whereas for method C, 46% of bound protein was
360 eluted. As a result of these studies, MPs_Dex with ligand 22/8
361 immobilized by Method C (MPs_Dex_228) appear as the
362 most promising magnetic supports with a binding capacity of
363 130 ± 5 mg of hIgG/g of MPs and a elution capacity of 60.1 ±
364 0.7 mg of hIgG/g of MPs, and further studies were performed
365 with this magnetic support.
366 MPs_Dex_22/8 were tested for binding to a model
367 contaminant protein, bovine serum albumin (BSA), for which
368 the support should not present affinity. The magnetic support
369 bound 12 ± 2 mg of BSA/g of MP, a 10-fold lower value when
370 compared to the quantity of hIgG bound (130 ± 5 mg of hIgG
371 bound/g of MP) (Figure 3B). The regeneration and reuse
372 capacity of the particles was also studied. As shown in Figure
373 3C particles retain about 70% of the initial protein binding and
374 elution capacity until the fifth stage of recycling. The pH
375 resistance of the support was evaluated in order to assess the
376 release of iron and dextran and therefore infer on eventual
377 ligand leaching, which is covalently bound to the polymer. The
378 total amount of dextran released after using five times the
379 support, was 0.0007% of the total amount of dextran initially
380 adsorbed, and during the first and second cycle of reutilization
381 there was no dextran release. In terms of magnetite release, we
382 observed that after five cycles of reutilization the support lost
383 0.39% of the initial magnetite which corresponded to 19 ng of
384 iron. In the first cycle of reutilization there was a leaching of
385 0.09 mg/L Fe (corresponding to 0.0006% of initial iron) during
386 the elution step, that is comparable with the results of Batalha
387 and co-workers.21 These observations, together with the
388 retention of protein attached to the support after elution and
389 regeneration, can account for the loss of capacity of the support
390 throughout the reutilization cycles.
391 The adsorption isotherm of human IgG on the magnetic
392 support MPs_Dex_22/8 (Figure 3D) was fitted in a Langmuir
393 type isotherm and compared with data available in the literature
t1 394 (Table 1). The experimental adsorption values of human IgG
395 on MPs_Dex_22/8 was found to be 130 mg of hIgG adsorbed/
396 g of MPs. The commercially available protein A modified MPs
397 show experimental adsorption of 109 mg hIgG adsorbed/g
398 MPs.37 Through the fitting of the adsorption curve of hIgG, an
399 affinity constant of 7.7 × 104 M−1 (Ka) and a theoretical
400maximum capacity of 568 ± 33 mg hIgG adsorbed/g MPs
401(Qmax) were obtained with a correlation factor of 0.95.The
402affinity constant value is in the same order of magnitude to the
403Protein A and ligand 22/8 immobilized on different supports.
404The Qmax value for MPs_Dex_22/8 is nearly two times higher
405than the same ligand immobilized on MPs_GA,21 four times
406higher than the same ligand immobilized on agarose and thirty
407times higher than the natural Protein A immobilized on
408agarose.7 Only the cellulose membrane revealed a higher
409binding capacity, which was not compensated by the low
410recovering capacity shown by this support.32
411The magnetic support MPs_Dex_22/8 was finally employed
412in the small-scale purification of an IgG monoclonal antibody
413 f4directly from CHO cell culture supernatants (Figure 4 - A)
414without any initial step to remove impurities. The recovery of
415pure IgG was visible at pH 3 and pH 11, but in larger yields for
416the latter. From 56% of total protein bound to the support,
417there was a recovery of 5 and 16% of total protein at pH 3 and
41811, respectively (Figure 4C). Through analysis of the 2D gel by
419densitometry analysis with software Image J, it was estimated
420that the loading sample contains about 60% of IgG (in terms of
421total protein present) and that the purified IgG presents 95%
422purity. The inertness of the MPs_Dex particles was also
423assessed (Figure 4B) with the crude samples, showing the
424absence of protein bound to or eluted from the support.
4. CONCLUSION
425Iron oxide magnetic particles with a dextran coating are a
426promising support for the magnetic separation of biomolecules,
427because of the ease of preparation and chemical modification,
428low cost, reduced nonspecific adsorption, and high stability. In
429particular, the covalent attachment of a synthetic affinity ligand
430mimicking protein A turned these particles viable for the one-
431step recovery of IgG. Our results show that the direct synthesis
432of the ligand on the magnetic support yielded the best
433antibody-capturing properties. In addition, this support
434MPs_Dex_22/8 also showed low nonspecific adsorption in
435the presence of BSA and no major loss of capacity after five
436cycles of protein purification. Moreover the estimated values for
437affinity constant for ligand 22/8 were comparable with those
438found for protein A and ligand 22/8 immobilized on different
439adsorbents, but with the advantage of presenting considerable
440higher maximum capacity for antibody adsorption. When
441contacting the magnetic adsorbent with mammalian cell culture
442supernatants rich in IgG, the MPs_Dex_22/8 supports were
443able to purify IgG when eluting at pH11 with a purity of 95%.
Table 1. Comparison of Binding Isotherm of Human IgG to
Immobilized Protein A and Ligand 22/8 onto Different
Supports and to Ligand 22/8 Immobilized on MPs_Dex
through Method C
support Ka (M−1)
Qmax (mg of hIgG adsorbed/g of
nsupport)
protein A on agarose 3.7 × 105 17
commercial protein A on
MPs
3.3 × 105 109
ligand 22/8 on agarose 1.4 × 105 152
ligand 22/8 on cellulose
membrane
3.0 × 105 630
Ligand 22/8 on MPs_Ga 1.5 × 105 344
ligand 22/8 on MPs_Dex 7.7 × 105 568
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466 ■ ABBREVIATIONS
467 MPs, oxide magnetic particles; MPs_Dex, iron oxide magnetic
468 particles coated with dextran; MPs_GA, iron oxide magnetic
469 particles coated with gum Arabic; MPs_Dex_22/8, iron oxide
470 magnetic particles coated with dextran modified with ligand 22/
471 8; hIgG, human IgG; BSA, bovine serum albumine
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